Posted on

MARA Announces Second Quarter 2026 Results

Miami, FL, Aug. 06, 2026 (GLOBE NEWSWIRE) — MARA Holdings, Inc. (NASDAQ: MARA) (“MARA” or the “Company”), a leading digital infrastructure company, today announced its preliminary, unaudited second quarter 2026 financial results in a letter to shareholders.

By sf-admin
Posted on

iRhythm to Acquire VitalConnect, Expanding Its Cardiac Monitoring Platform Across Ambulatory, Inpatient and Hospital-to-Home Care

SAN FRANCISCO, Aug. 06, 2026 (GLOBE NEWSWIRE) — iRhythm Holdings, Inc. (Nasdaq: IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict and prevent disease, today announced that it and its wholly owned subsidiary, iRhythm Technologies, Inc., have entered into a definitive agreement to acquire Vital Connect, Inc. (“VitalConnect”), a privately held leader in wearable biosensor technology and ambulatory cardiac monitoring.

By sf-admin
Posted on

Broad Arrow Private Sales Presents Rare Lexus LFA Nürburgring Package and Marc Philipp Gemballa Marsien at The Quail by The Peninsula, A Motorsports Gathering

Broad Arrow Private Sales brings the most collectible Japanese supercar of the modern era to market, a 2012 Lexus LFA Nürburgring Package | One of only 64 hand-assembled LFA Nürburgring Package models, finished in Whitest White and showing only 72 miles | Joined by extremely rare Gemballa MARSIEN, both available through Broad Arrow Private Sales and on display at The Quail by The Peninsula, A Motorsports Gathering | Broad Arrow’s ‘The Quail Auction’, set for August 13-14, is the official auction partner of The Quail by The Peninsula, A Motorsports Gathering | Additional details on each car available at broadarrowprivatesales.com 

Broad Arrow Private Sales brings the most collectible Japanese supercar of the modern era to market, a 2012 Lexus LFA Nürburgring Package | One of only 64 hand-assembled LFA Nürburgring Package models, finished in Whitest White and showing only 72 miles | Joined by extremely rare Gemballa MARSIEN, both available through Broad Arrow Private Sales and on display at The Quail by The Peninsula, A Motorsports Gathering | Broad Arrow’s ‘The Quail Auction’, set for August 13-14, is the official auction partner of The Quail by The Peninsula, A Motorsports Gathering | Additional details on each car available at broadarrowprivatesales.com

By sf-admin
Posted on

Continuim Equity Partners Closes Oversubscribed Fund III at $548 Million – Bringing AUM to Over $1 Billion

PITTSBURGH, Aug. 06, 2026 (GLOBE NEWSWIRE) — Continuim Equity Partners, LP (“Continuim” or the “Firm”), a Pittsburgh-based private equity firm focused on acquiring and accelerating the growth of manufacturing and industrial businesses, is pleased to announce the close of Continuim Equity Partners Fund III, LP (together with its parallel investment vehicles, “Fund III”) with $548 million in total commitments. Fund III was significantly oversubscribed and closed after 32 days in market – bringing the Firm’s assets under management to over $1 billion.

By sf-admin
Posted on

Global Regenerative Medicine Market is Projected to Cross the USD 160 Billion Mark by 2034 | DelveInsight

The regenerative medicine market is witnessing robust growth, driven by advances in stem cell therapies, gene editing, tissue engineering, and biomaterials. Rising prevalence of chronic diseases, musculoskeletal disorders, and organ failure is increasing demand for therapies that restore or replace damaged tissues rather than simply manage symptoms. Continued investment in research and development, expanding clinical pipelines, and supportive regulatory initiatives are accelerating innovation and commercialization. As more regenerative therapies gain regulatory approvals and manufacturing capabilities improve, the market is expected to experience sustained expansion over the coming years. 

The regenerative medicine market is witnessing robust growth, driven by advances in stem cell therapies, gene editing, tissue engineering, and biomaterials. Rising prevalence of chronic diseases, musculoskeletal disorders, and organ failure is increasing demand for therapies that restore or replace damaged tissues rather than simply manage symptoms. Continued investment in research and development, expanding clinical pipelines, and supportive regulatory initiatives are accelerating innovation and commercialization. As more regenerative therapies gain regulatory approvals and manufacturing capabilities improve, the market is expected to experience sustained expansion over the coming years.

By sf-admin